On October 20, 2023, the board of directors of Quince Therapeutics, Inc. appointed Luca Benatti to serve as a director of the Company, effective as of the first business day following the closing of the EryDel Acquisition. Mr. Benatti was designated as a Class II director whose term expires at the Company?s 2024 Annual Meeting of Stockholders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.92 USD | -4.17% | -14.02% | -12.38% |
04-01 | Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-26 | Transcript : Quince Therapeutics, Inc. - Special Call |
1st Jan change | Capi. | |
---|---|---|
-12.38% | 41.49M | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- QNCX Stock
- News Quince Therapeutics, Inc.
- Quince Therapeutics, Inc. Appoints Luca Benatti as Director